Tumor Microsatellite-Instability Status as a Predictor of Benefit from Fluorouracil-Based Adjuvant Chemotherapy for Colon Cancer
Christine M. Ribic, M.Sc., Daniel J. Sargent, Ph.D., Malcolm J. Moore, M.D., Stephen N. Thibodeau, Ph.D., Amy J. French, B.A., Richard M. Goldberg, M.D., Stanley R. Hamilton, M.D., Pierre Laurent-Puig, M.D., Ph.D., Robert Gryfe, M.D., Ph.D., Lois E. Shepherd, M.D., Dongsheng Tu, Ph.D., Mark Redston, M.D., and Steven Gallinger, M.D.
Background Colon cancers with high-frequency microsatelliteinstability have clinical and pathological features that distinguishthem from microsatellite-stable tumors. We investigated theusefulness of microsatellite-instability status as a predictorof the benefit of adjuvant chemotherapy with fluorouracil instage II and stage III colon cancer.
Methods Tumor specimens were collected from patients with coloncancer who were enrolled in randomized trials of fluorouracil-basedadjuvant chemotherapy. Microsatellite instability was assessedwith the use of mononucleotide and dinucleotide markers.
Results Of 570 tissue specimens, 95 (16.7 percent) exhibitedhigh-frequency microsatellite instability. Among 287 patientswho did not receive adjuvant therapy, those with tumors displayinghigh-frequency microsatellite instability had a better five-yearrate of overall survival than patients with tumors exhibitingmicrosatellite stability or low-frequency instability (hazardratio for death, 0.31 [95 percent confidence interval, 0.14to 0.72]; P=0.004). Among patients who received adjuvant chemotherapy,high-frequency microsatellite instability was not correlatedwith increased overall survival (hazard ratio for death, 1.07[95 percent confidence interval, 0.62 to 1.86]; P=0.80). Thebenefit of treatment differed significantly according to themicrosatellite-instability status (P=0.01). Adjuvant chemotherapyimproved overall survival among patients with microsatellite-stabletumors or tumors exhibiting low-frequency microsatellite instability,according to a multivariate analysis adjusted for stage andgrade (hazard ratio for death, 0.72 [95 percent confidence interval,0.53 to 0.99]; P=0.04). By contrast, there was no benefit ofadjuvant chemotherapy in the group with high-frequency microsatelliteinstability.
Conclusions Fluorouracil-based adjuvant chemotherapy benefitedpatients with stage II or stage III colon cancer with microsatellite-stabletumors or tumors exhibiting low-frequency microsatellite instabilitybut not those with tumors exhibiting high-frequency microsatelliteinstability.
Source Information
From the Centre for Cancer Genetics, Samuel Lunenfeld Research Institute (C.M.R., R.G., S.G.), the Department of Medicine and Surgery, Princess Margaret Hospital (M.J.M., S.G.), and the Department of Surgery, Mount Sinai Hospital (R.G., S.G.), University of Toronto, Toronto; the Division of Biostatistics (D.J.S.), the Division of Medical Oncology (R.M.G.), and the Department of Laboratory Medicine and Pathology (S.N.T., A.J.F.), Mayo Foundation, Rochester, Minn.; the Clinical Trials Group, National Cancer Institute of Canada, Queen's University, Kingston, Ont. (M.J.M., L.E.S., D.T., S.G.); the Eastern Cooperative Oncology Group, Brookline, Mass. (S.R.H.); the M.D. Anderson Cancer Center, Houston (S.R.H.); the Fédération Francophone de Cancérologie Digestive, Paris (P.L.-P.); and Brigham and Women's Hospital, Boston (M.R.).
Address reprint requests to Dr. Gallinger at Mount Sinai Hospital, 600 University Ave., Suite 1225, Toronto, ON M5G 1X5, Canada, or at sgallinger{at}mtsinai.on.ca.
Microsatellite Instability in Colon Cancer
Allegra C. J., Kim G., Kirsch I. R., Iacopetta B., Elsaleh H., Zeps N., Jimenez J. J., Blanes A., Diaz-Cano S. J., Gryfe R., Ribic C. M., Sargent D. J.
Extract |
Full Text |
PDF
N Engl J Med 2003;
349:1774-1776, Oct 30, 2003.
Correspondence
This article has been cited by other articles:
Zaanan, A., Cuilliere-Dartigues, P., Guilloux, A., Parc, Y., Louvet, C., de Gramont, A., Tiret, E., Dumont, S., Gayet, B., Validire, P., Flejou, J.-F., Duval, A., Praz, F.
(2009). Impact of p53 expression and microsatellite instability on stage III colon cancer disease-free survival in patients treated by 5-fluorouracil and leucovorin with or without oxaliplatin. Ann Oncol
0: mdp383v1-mdp383
[Abstract][Full Text]
Yuan, Z., Shin, J., Wilson, A., Goel, S., Ling, Y.-H., Ahmed, N., Dopeso, H., Jhawer, M., Nasser, S., Montagna, C., Fordyce, K., Augenlicht, L. H., Aaltonen, L. A., Arango, D., Weber, T. K., Mariadason, J. M.
(2009). An A13 Repeat within the 3'-Untranslated Region of Epidermal Growth Factor Receptor (EGFR) Is Frequently Mutated in Microsatellite Instability Colon Cancers and Is Associated with Increased EGFR Expression. Cancer Res.
69: 7811-7818
[Abstract][Full Text]
Kim, J. G., Chae, Y. S., Sohn, S. K., Moon, J. H., Kang, B. W., Park, J. Y., Jeon, S. W., Lee, M.-H., Lim, K.-H., Choi, G. S., Jun, S.-H.
(2009). IVS10+12A>G polymorphism in hMSH2 gene associated with prognosis for patients with colorectal cancer. Ann Oncol
0: mdp338v1-mdp338
[Abstract][Full Text]
Kumar, S., Chang, E. Y., Frankhouse, J., Dorsey, P. B., Lee, R. G., Johnson, N.
(2009). Combination of Microsatellite Instability and Lymphocytic Infiltrate as a Prognostic Indicator for Adjuvant Therapy in Colon Cancer. Arch Surg
144: 835-840
[Abstract][Full Text]
Edwards, R. A., Witherspoon, M., Wang, K., Afrasiabi, K., Pham, T., Birnbaumer, L., Lipkin, S. M.
(2009). Epigenetic Repression of DNA Mismatch Repair by Inflammation and Hypoxia in Inflammatory Bowel Disease-Associated Colorectal Cancer. Cancer Res.
69: 6423-6429
[Abstract][Full Text]
Kauff, N. D.
(2009). ATR Mutations in Endometrial Cancer: A Window Into the Role of Mismatch Repair Defects. JCO
27: 3077-3078
[Full Text]
Postma, C., Koopman, M., Buffart, T. E., Eijk, P. P., Carvalho, B., Peters, G. J., Ylstra, B., van Krieken, J. H., Punt, C. J. A., Meijer, G. A.
(2009). DNA copy number profiles of primary tumors as predictors of response to chemotherapy in advanced colorectal cancer. Ann Oncol
20: 1048-1056
[Abstract][Full Text]
Bianchi, F., Galizia, E., Catalani, R., Belvederesi, L., Ferretti, C., Corradini, F., Cellerino, R.
(2009). CAT25 Is a Mononucleotide Marker to Identify HNPCC Patients. J. Mol. Diagn.
11: 248-252
[Abstract][Full Text]
DES GUETZ, G., UZZAN, B., NICOLAS, P., SCHISCHMANOFF, O., PERRET, G.-Y., MORERE, J.-F.
(2009). Microsatellite Instability does not Predict the Efficacy of Chemotherapy in Metastatic Colorectal Cancer. A Systematic Review and Meta-analysis. Anticancer Res
29: 1615-1620
[Abstract][Full Text]
Paya, A., Alenda, C., Perez-Carbonell, L., Rojas, E., Soto, J.-L., Guillen, C., Castillejo, A., Barbera, V. M., Carrato, A., Castells, A., Llor, X., Andreu, M., Koh, J., Enders, G. H., Benlloch, S., Jover, R.
(2009). Utility of p16 Immunohistochemistry for the Identification of Lynch Syndrome. Clin. Cancer Res.
15: 3156-3162
[Abstract][Full Text]
Vilar, E., Mukherjee, B., Kuick, R., Raskin, L., Misek, D. E., Taylor, J. M.G., Giordano, T. J., Hanash, S. M., Fearon, E. R., Rennert, G., Gruber, S. B.
(2009). Gene Expression Patterns in Mismatch Repair-Deficient Colorectal Cancers Highlight the Potential Therapeutic Role of Inhibitors of the Phosphatidylinositol 3-Kinase-AKT-Mammalian Target of Rapamycin Pathway. Clin. Cancer Res.
15: 2829-2839
[Abstract][Full Text]
Bertagnolli, M. M., Niedzwiecki, D., Compton, C. C., Hahn, H. P., Hall, M., Damas, B., Jewell, S. D., Mayer, R. J., Goldberg, R. M., Saltz, L. B., Warren, R. S., Redston, M.
(2009). Microsatellite Instability Predicts Improved Response to Adjuvant Therapy With Irinotecan, Fluorouracil, and Leucovorin in Stage III Colon Cancer: Cancer and Leukemia Group B Protocol 89803. JCO
27: 1814-1821
[Abstract][Full Text]
Brody, J. R., Hucl, T., Costantino, C. L., Eshleman, J. R., Gallmeier, E., Zhu, H., van der Heijden, M. S., Winter, J. M., Wikiewicz, A. K., Yeo, C. J., Kern, S. E.
(2009). Limits to Thymidylate Synthase and TP53 Genes as Predictive Determinants for Fluoropyrimidine Sensitivity and Further Evidence for RNA-Based Toxicity as a Major Influence. Cancer Res.
69: 984-991
[Abstract][Full Text]
Lenz, H.-J.
(2009). Established Biomarkers for Colon Cancer. Am Soc Clin Oncol Ed Book
2009: 215-219
[Abstract][Full Text]
Sturgeon, C. M., Duffy, M. J., Stenman, U.-H., Lilja, H., Brunner, N., Chan, D. W., Babaian, R., Bast, R. C. Jr., Dowell, B., Esteva, F. J., Haglund, C., Harbeck, N., Hayes, D. F., Holten-Andersen, M., Klee, G. G., Lamerz, R., Looijenga, L. H., Molina, R., Nielsen, H. J., Rittenhouse, H., Semjonow, A., Shih, I.-M., Sibley, P., Soletormos, G., Stephan, C., Sokoll, L., Hoffman, B. R., Diamandis, E. P.
(2008). National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Testicular, Prostate, Colorectal, Breast, and Ovarian Cancers. Clin. Chem.
54: e11-e79
[Abstract][Full Text]
Pal, T., Permuth-Wey, J., Kumar, A., Sellers, T. A.
(2008). Systematic Review and Meta-analysis of Ovarian Cancers: Estimation of Microsatellite-High Frequency and Characterization of Mismatch Repair Deficient Tumor Histology. Clin. Cancer Res.
14: 6847-6854
[Abstract][Full Text]
Brait, M., Begum, S., Carvalho, A. L., Dasgupta, S., Vettore, A. L., Czerniak, B., Caballero, O. L., Westra, W. H., Sidransky, D., Hoque, M. O.
(2008). Aberrant Promoter Methylation of Multiple Genes during Pathogenesis of Bladder Cancer. Cancer Epidemiol. Biomarkers Prev.
17: 2786-2794
[Abstract][Full Text]
Schepeler, T., Reinert, J. T., Ostenfeld, M. S., Christensen, L. L., Silahtaroglu, A. N., Dyrskjot, L., Wiuf, C., Sorensen, F. J., Kruhoffer, M., Laurberg, S., Kauppinen, S., Orntoft, T. F., Andersen, C. L.
(2008). Diagnostic and Prognostic MicroRNAs in Stage II Colon Cancer. Cancer Res.
68: 6416-6424
[Abstract][Full Text]
Zlobec, I, Lugli, A
(2008). Prognostic and predictive factors in colorectal cancer. Postgrad. Med. J.
84: 403-411
[Abstract][Full Text]
Carethers, J. M.
(2008). Review: Systemic treatment of advanced colorectal cancer: Tailoring therapy to the tumor. Therapeutic Advances in Gastroenterology
1: 33-42
[Abstract]
Zlobec, I., Baker, K., Terracciano, L. M., Lugli, A.
(2008). RHAMM, p21 Combined Phenotype Identifies Microsatellite Instability-High Colorectal Cancers with a Highly Adverse Prognosis. Clin. Cancer Res.
14: 3798-3806
[Abstract][Full Text]
Braun, M. S., Richman, S. D., Quirke, P., Daly, C., Adlard, J. W., Elliott, F., Barrett, J. H., Selby, P., Meade, A. M., Stephens, R. J., Parmar, M. K.B., Seymour, M. T.
(2008). Predictive Biomarkers of Chemotherapy Efficacy in Colorectal Cancer: Results From the UK MRC FOCUS Trial. JCO
26: 2690-2698
[Abstract][Full Text]
French, A. J., Sargent, D. J., Burgart, L. J., Foster, N. R., Kabat, B. F., Goldberg, R., Shepherd, L., Windschitl, H. E., Thibodeau, S. N.
(2008). Prognostic Significance of Defective Mismatch Repair and BRAF V600E in Patients with Colon Cancer. Clin. Cancer Res.
14: 3408-3415
[Abstract][Full Text]
Soong, R., Shah, N., Salto-Tellez, M., Tai, B. C., Soo, R. A., Han, H. C., Ng, S. S., Tan, W. L., Zeps, N., Joseph, D., Diasio, R. B., Iacopetta, B.
(2008). Prognostic significance of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase protein expression in colorectal cancer patients treated with or without 5-fluorouracil-based chemotherapy. Ann Oncol
19: 915-919
[Abstract][Full Text]
Zlobec, I, Lugli, A
(2008). Prognostic and predictive factors in colorectal cancer. J. Clin. Pathol.
61: 561-569
[Abstract][Full Text]
Imai, K., Yamamoto, H.
(2008). Carcinogenesis and microsatellite instability: the interrelationship between genetics and epigenetics. Carcinogenesis
29: 673-680
[Abstract][Full Text]
Deschoolmeester, V., Baay, M., Wuyts, W., Van Marck, E., Van Damme, N., Vermeulen, P., Lukaszuk, K., Lardon, F., Vermorken, J. B.
(2008). Detection of Microsatellite Instability in Colorectal Cancer Using an Alternative Multiplex Assay of Quasi-Monomorphic Mononucleotide Markers. J. Mol. Diagn.
10: 154-159
[Abstract][Full Text]
Ogino, S., Goel, A.
(2008). Molecular Classification and Correlates in Colorectal Cancer. J. Mol. Diagn.
10: 13-27
[Abstract][Full Text]
Kim, G. P., Colangelo, L. H., Paik, S., O'Connell, M. J., Kirsch, I. R., Allegra, C., Wolmark, N.
(2007). Predictive Value of Microsatellite Instability-High Remains Controversial. JCO
25: 4857-4857
[Full Text]
Lonning, P., Knappskog, S, Staalesen, V, Chrisanthar, R, Lillehaug, J.
(2007). Breast cancer prognostication and prediction in the postgenomic era. Ann Oncol
18: 1293-1306
[Abstract][Full Text]
Malesci, A., Laghi, L., Bianchi, P., Delconte, G., Randolph, A., Torri, V., Carnaghi, C., Doci, R., Rosati, R., Montorsi, M., Roncalli, M., Gennari, L., Santoro, A.
(2007). Reduced Likelihood of Metastases in Patients with Microsatellite-Unstable Colorectal Cancer. Clin. Cancer Res.
13: 3831-3839
[Abstract][Full Text]
Kazama, Y., Watanabe, T., Kanazawa, T., Tanaka, J., Tanaka, T., Nagawa, H.
(2007). Microsatellite instability in poorly differentiated adenocarcinomas of the colon and rectum: relationship to clinicopathological features. J. Clin. Pathol.
60: 701-704
[Abstract][Full Text]
Vasen, H F A, Moslein, G, Alonso, A, Bernstein, I, Bertario, L, Blanco, I, Burn, J, Capella, G, Engel, C, Frayling, I, Friedl, W, Hes, F J, Hodgson, S, Mecklin, J-P, Moller, P, Nagengast, F, Parc, Y, Renkonen-Sinisalo, L, Sampson, J R, Stormorken, A, Wijnen, J
(2007). Guidelines for the clinical management of Lynch syndrome (hereditary non-polyposis cancer). J. Med. Genet.
44: 353-362
[Abstract][Full Text]
Yates, D. R., Rehman, I., Abbod, M. F., Meuth, M., Cross, S. S., Linkens, D. A., Hamdy, F. C., Catto, J. W.F.
(2007). Promoter Hypermethylation Identifies Progression Risk in Bladder Cancer. Clin. Cancer Res.
13: 2046-2053
[Abstract][Full Text]
Del Rio, M., Molina, F., Bascoul-Mollevi, C., Copois, V., Bibeau, F., Chalbos, P., Bareil, C., Kramar, A., Salvetat, N., Fraslon, C., Conseiller, E., Granci, V., Leblanc, B., Pau, B., Martineau, P., Ychou, M.
(2007). Gene Expression Signature in Advanced Colorectal Cancer Patients Select Drugs and Response for the Use of Leucovorin, Fluorouracil, and Irinotecan. JCO
25: 773-780
[Abstract][Full Text]
Kim, G. P., Colangelo, L. H., Wieand, H. S., Paik, S., Kirsch, I. R., Wolmark, N., Allegra, C. J.
(2007). Prognostic and Predictive Roles of High-Degree Microsatellite Instability in Colon Cancer: A National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project Collaborative Study. JCO
25: 767-772
[Abstract][Full Text]
Boland, C. R.
(2007). Clinical Uses of Microsatellite Instability Testing in Colorectal Cancer: An Ongoing Challenge. JCO
25: 754-756
[Full Text]
Wong, J J L, Hawkins, N J, Ward, R L
(2007). Colorectal cancer: a model for epigenetic tumorigenesis. Gut
56: 140-148
[Full Text]
Carethers, J M
(2006). Authors' reply.. Gut
55: 1819-1819
[Full Text]
Jover, R, Castells, A, Llor, X, Andreu, M
(2006). Authors' reply.. Gut
55: 1819-1820
[Full Text]
Locker, G. Y., Hamilton, S., Harris, J., Jessup, J. M., Kemeny, N., Macdonald, J. S., Somerfield, M. R., Hayes, D. F., Bast, R. C. Jr
(2006). ASCO 2006 Update of Recommendations for the Use of Tumor Markers in Gastrointestinal Cancer. JCO
24: 5313-5327
[Abstract][Full Text]
Rosen, L. S., Abdi, E., Davis, I. D., Gutheil, J., Schnell, F. M., Zalcberg, J., Cesano, A., Gayko, U., Chen, M.-G., Clarke, S.
(2006). Palifermin Reduces the Incidence of Oral Mucositis in Patients With Metastatic Colorectal Cancer Treated With Fluorouracil-Based Chemotherapy. JCO
24: 5194-5200
[Abstract][Full Text]
Iacopetta, B, Watanabe, T
(2006). Predictive value of microsatellite instability for benefit from adjuvant fluorouracil chemotherapy in colorectal cancer.. Gut
55: 1671-1672
[Full Text]
Leong, A S-Y, Leong, T Y-M
(2006). Newer developments in immunohistology.. J. Clin. Pathol.
59: 1117-1126
[Abstract][Full Text]
Trautmann, K., Terdiman, J. P., French, A. J., Roydasgupta, R., Sein, N., Kakar, S., Fridlyand, J., Snijders, A. M., Albertson, D. G., Thibodeau, S. N., Waldman, F. M.
(2006). Chromosomal Instability in Microsatellite-Unstable and Stable Colon Cancer.. Clin. Cancer Res.
12: 6379-6385
[Abstract][Full Text]
Schurr, P., Wolter, S., Kaifi, J., Reichelt, U., Kleinhans, H., Wachowiak, R., Yekebas, E., Strate, T., Kalinin, V., Simon, R., Sauter, G., Schaefer, H., Izbicki, J.
(2006). Microsatellite DNA Alterations of Gastrointestinal Stromal Tumors Are Predictive for Outcome. Clin. Cancer Res.
12: 5151-5157
[Abstract][Full Text]
Iacopetta, B, Li, W Q, Grieu, F, Ruszkiewicz, A, Kawakami, K
(2006). BRAF mutation and gene methylation frequencies of colorectal tumours with microsatellite instability increase markedly with patient age.. Gut
55: 1213-1213
[Full Text]
Murphy, K. M., Zhang, S., Geiger, T., Hafez, M. J., Bacher, J., Berg, K. D., Eshleman, J. R.
(2006). Comparison of the Microsatellite Instability Analysis System and the Bethesda Panel for the Determination of Microsatellite Instability in Colorectal Cancers. J. Mol. Diagn.
8: 305-311
[Abstract][Full Text]
Barnetson, R. A., Tenesa, A., Farrington, S. M., Nicholl, I. D., Cetnarskyj, R., Porteous, M. E., Campbell, H., Dunlop, M. G.
(2006). Identification and survival of carriers of mutations in DNA mismatch-repair genes in colon cancer.. NEJM
354: 2751-2763
[Abstract][Full Text]
Watanabe, T., Kanazawa, T., Kazama, Y., Tanaka, J., Tanaka, T., Ishihara, S., Nagawa, H., Benatti, P., Ponz de Leon, M., Gafa, R., Lanza, G., Barana, D., Oliani, C.
(2006). Adjuvant chemotherapy in colorectal cancer patients with microsatellite instability.. Clin. Cancer Res.
12: 3866-3867
[Full Text]
Carethers, J M
(2006). Prospective evaluation of fluorouracil chemotherapy based on the genetic makeup of colorectal cancer.. Gut
55: 759-761
[Full Text]
Jover, R, Zapater, P, Castells, A, Llor, X, Andreu, M, Cubiella, J, Pinol, V, Xicola, R M, Bujanda, L, Rene, J M, Clofent, J, Bessa, X, Morillas, J D, Nicolas-Perez, D, Paya, A, Alenda, C, for the Gastrointestinal Oncology Group of the Spa,
(2006). Mismatch repair status in the prediction of benefit from adjuvant fluorouracil chemotherapy in colorectal cancer. Gut
55: 848-855
[Abstract][Full Text]
Lanza, G., Gafa, R., Santini, A., Maestri, I., Guerzoni, L., Cavazzini, L.
(2006). Immunohistochemical Test for MLH1 and MSH2 Expression Predicts Clinical Outcome in Stage II and III Colorectal Cancer Patients. JCO
24: 2359-2367
[Abstract][Full Text]
Sinicrope, F. A., Rego, R. L., Halling, K. C., Foster, N. R., Sargent, D. J., La Plant, B., French, A. J., Allegra, C. J., Laurie, J. A., Goldberg, R. M., Witzig, T. E., Thibodeau, S. N.
(2006). Thymidylate synthase expression in colon carcinomas with microsatellite instability.. Clin. Cancer Res.
12: 2738-2744
[Abstract][Full Text]
Buhard, O., Cattaneo, F., Wong, Y. F., Yim, S. F., Friedman, E., Flejou, J.-F., Duval, A., Hamelin, R.
(2006). Multipopulation Analysis of Polymorphisms in Five Mononucleotide Repeats Used to Determine the Microsatellite Instability Status of Human Tumors. JCO
24: 241-251
[Abstract][Full Text]
Benatti, P., Gafa, R., Barana, D., Marino, M., Scarselli, A., Pedroni, M., Maestri, I., Guerzoni, L., Roncucci, L., Menigatti, M., Roncari, B., Maffei, S., Rossi, G., Ponti, G., Santini, A., Losi, L., Di Gregorio, C., Oliani, C., Ponz de Leon, M., Lanza, G.
(2005). Microsatellite Instability and Colorectal Cancer Prognosis. Clin. Cancer Res.
11: 8332-8340
[Abstract][Full Text]
Giacomini, C. P., Leung, S. Y., Chen, X., Yuen, S. T., Kim, Y. H., Bair, E., Pollack, J. R.
(2005). A Gene Expression Signature of Genetic Instability in Colon Cancer. Cancer Res.
65: 9200-9205
[Abstract][Full Text]
Findeisen, P., Kloor, M., Merx, S., Sutter, C., Woerner, S. M., Dostmann, N., Benner, A., Dondog, B., Pawlita, M., Dippold, W., Wagner, R., Gebert, J., von Knebel Doeberitz, M.
(2005). T25 Repeat in the 3' Untranslated Region of the CASP2 Gene: A Sensitive and Specific Marker for Microsatellite Instability in Colorectal Cancer. Cancer Res.
65: 8072-8078
[Abstract][Full Text]
Westra, J. L., Schaapveld, M., Hollema, H., de Boer, J. P., Kraak, M. M.J., de Jong, D., ter Elst, A., Mulder, N. H., Buys, C. H.C.M., Hofstra, R. M.W., Plukker, J. T.M.
(2005). Determination of TP53 Mutation Is More Relevant Than Microsatellite Instability Status for the Prediction of Disease-Free Survival in Adjuvant-Treated Stage III Colon Cancer Patients. JCO
23: 5635-5643
[Abstract][Full Text]
Eaton, A. M., Sandler, R., Carethers, J. M., Millikan, R. C., Galanko, J., Keku, T. O.
(2005). 5,10-Methylenetetrahydrofolate Reductase 677 and 1298 Polymorphisms, Folate Intake, and Microsatellite Instability in Colon Cancer. Cancer Epidemiol. Biomarkers Prev.
14: 2023-2029
[Abstract][Full Text]
Negri, F. V., Wotherspoon, A., Cunningham, D., Norman, A. R., Chong, G., Ross, P. J.
(2005). Mucinous histology predicts for reduced fluorouracil responsiveness and survival in advanced colorectal cancer. Ann Oncol
16: 1305-1310
[Abstract][Full Text]
Ricciardiello, L., Ceccarelli, C., Angiolini, G., Pariali, M., Chieco, P., Paterini, P., Biasco, G., Martinelli, G. N., Roda, E., Bazzoli, F.
(2005). High Thymidylate Synthase Expression in Colorectal Cancer with Microsatellite Instability: Implications for Chemotherapeutic Strategies. Clin. Cancer Res.
11: 4234-4240
[Abstract][Full Text]
Hampel, H., Frankel, W. L., Martin, E., Arnold, M., Khanduja, K., Kuebler, P., Nakagawa, H., Sotamaa, K., Prior, T. W., Westman, J., Panescu, J., Fix, D., Lockman, J., Comeras, I., de la Chapelle, A.
(2005). Screening for the Lynch Syndrome (Hereditary Nonpolyposis Colorectal Cancer). NEJM
352: 1851-1860
[Abstract][Full Text]
Baddi, L., Benson, A. III
(2005). Adjuvant Therapy in Stage II Colon Cancer: Current Approaches. The Oncologist
10: 325-331
[Full Text]
Johnston, P. G.
(2005). Stage II Colorectal Cancer: To Treat or not to Treat. The Oncologist
10: 332-334
[Full Text]
Kohonen-Corish, M. R.J., Daniel, J. J., Chan, C., Lin, B. P.C., Kwun, S. Y., Dent, O. F., Dhillon, V. S., Trent, R. J.A., Chapuis, P. H., Bokey, E. L.
(2005). Low Microsatellite Instability Is Associated With Poor Prognosis in Stage C Colon Cancer. JCO
23: 2318-2324
[Abstract][Full Text]
Popat, S., Matakidou, A., Houlston, R. S.
(2005). In Reply:. JCO
23: 2108-2109
[Full Text]
Hatch, S. B., Lightfoot, H. M. Jr., Garwacki, C. P., Moore, D. T., Calvo, B. F., Woosley, J. T., Sciarrotta, J., Funkhouser, W. K., Farber, R. A.
(2005). Microsatellite Instability Testing in Colorectal Carcinoma: Choice of Markers Affects Sensitivity of Detection of Mismatch Repair-Deficient Tumors. Clin. Cancer Res.
11: 2180-2187
[Abstract][Full Text]
Meyers, M., Wagner, M. W., Mazurek, A., Schmutte, C., Fishel, R., Boothman, D. A.
(2005). DNA Mismatch Repair-dependent Response to Fluoropyrimidine-generated Damage. J. Biol. Chem.
280: 5516-5526
[Abstract][Full Text]
Popat, S., Hubner, R., Houlston, R.S.
(2005). Systematic Review of Microsatellite Instability and Colorectal Cancer Prognosis. JCO
23: 609-618
[Abstract][Full Text]
Alberts, S. R., Sargent, D. J., Gill, S., Loprinzi, C. L.
(2005). In Reply. JCO
23: 654-655
[Full Text]
Wright, C M, Dent, O F, Newland, R C, Barker, M, Chapuis, P H, Bokey, E L, Young, J P, Leggett, B A, Jass, J R, Macdonald, G A
(2005). Low level microsatellite instability may be associated with reduced cancer specific survival in sporadic stage C colorectal carcinoma. Gut
54: 103-108
[Abstract][Full Text]
Offit, K.
(2004). MSH6 Mutations in Hereditary Nonpolyposis Colon Cancer: Another Slice of the Pie. JCO
22: 4449-4451
[Full Text]
Seo, Y., Yan, T., Schupp, J. E., Colussi, V., Taylor, K. L., Kinsella, T. J.
(2004). Differential Radiosensitization in DNA Mismatch Repair-Proficient and -Deficient Human Colon Cancer Xenografts with 5-Iodo-2-pyrimidinone-2'-deoxyribose. Clin. Cancer Res.
10: 7520-7528
[Abstract][Full Text]
Potter, D. D., Murray, J. A., Donohue, J. H., Burgart, L. J., Nagorney, D. M., van Heerden, J. A., Plevak, M. F., Zinsmeister, A. R., Thibodeau, S. N.
(2004). The Role of Defective Mismatch Repair in Small Bowel Adenocarcinoma in Celiac Disease. Cancer Res.
64: 7073-7077
[Abstract][Full Text]
Laghi, L., Bianchi, P., Roncalli, M., Malesci, A.
(2004). Re: Revised Bethesda Guidelines for Hereditary Nonpolyposis Colorectal Cancer (Lynch Syndrome) and Microsatellite Instability. JNCI J Natl Cancer Inst
96: 1402-1403
[Full Text]
Zaniboni, A., Labianca, R.
(2004). Adjuvant therapy for stage II colon cancer: an elephant in the living room?. Ann Oncol
15: 1310-1318
[Abstract][Full Text]
Domingo, E, Laiho, P, Ollikainen, M, Pinto, M, Wang, L, French, A J, Westra, J, Frebourg, T, Espin, E, Armengol, M, Hamelin, R, Yamamoto, H, Hofstra, R M W, Seruca, R, Lindblom, A, Peltomaki, P, Thibodeau, S N, Aaltonen, L A, Schwartz, S Jr
(2004). BRAF screening as a low-cost effective strategy for simplifying HNPCC genetic testing. J. Med. Genet.
41: 664-668
[Abstract][Full Text]
Benson, A. B. III, Schrag, D., Somerfield, M. R., Cohen, A. M., Figueredo, A. T., Flynn, P. J., Krzyzanowska, M. K., Maroun, J., McAllister, P., Van Cutsem, E., Brouwers, M., Charette, M., Haller, D. G.
(2004). American Society of Clinical Oncology Recommendations on Adjuvant Chemotherapy for Stage II Colon Cancer. JCO
22: 3408-3419
[Abstract][Full Text]
Kambara, T, Simms, L A, Whitehall, V L J, Spring, K J, Wynter, C V A, Walsh, M D, Barker, M A, Arnold, S, McGivern, A, Matsubara, N, Tanaka, N, Higuchi, T, Young, J, Jass, J R, Leggett, B A
(2004). BRAF mutation is associated with DNA methylation in serrated polyps and cancers of the colorectum. Gut
53: 1137-1144
[Abstract][Full Text]
Salto-Tellez, M., Lee, S. C., Chiu, L. L., Lee, C. K., Yong, M. C., Koay, E. S.C.
(2004). Microsatellite Instability in Colorectal Cancer: Considerations for Molecular Diagnosis and High-Throughput Screening of Archival Tissues. Clin. Chem.
50: 1082-1086
[Full Text]
Gill, S., Loprinzi, C. L., Sargent, D. J., Thome, S. D., Alberts, S. R., Haller, D. G., Benedetti, J., Francini, G., Shepherd, L. E., Francois Seitz, J., Labianca, R., Chen, W., Cha, S. S., Heldebrant, M. P., Goldberg, R. M.
(2004). Pooled Analysis of Fluorouracil-Based Adjuvant Therapy for Stage II and III Colon Cancer: Who Benefits and by How Much?. JCO
22: 1797-1806
[Abstract][Full Text]
Garrity, M. M., Burgart, L. J., Mahoney, M. R., Windschitl, H. E., Salim, M., Wiesenfeld, M., Krook, J. E., Michalak, J. C., Goldberg, R. M., O'Connell, M. J., Furth, A. F., Sargent, D. J., Murphy, L. M., Hill, E., Riehle, D. L., Meyers, C. H., Witzig, T. E.
(2004). Prognostic Value of Proliferation, Apoptosis, Defective DNA Mismatch Repair, and p53 Overexpression in Patients With Resected Dukes' B2 or C Colon Cancer: A North Central Cancer Treatment Group Study. JCO
22: 1572-1582
[Abstract][Full Text]
Parc, Y, Gueroult, S, Mourra, N, Serfaty, L, Flejou, J-F, Tiret, E, Parc, R
(2004). Prognostic significance of microsatellite instability determined by immunohistochemical staining of MSH2 and MLH1 in sporadic T3N0M0 colon cancer. Gut
53: 371-375
[Abstract][Full Text]
Wild, P. J., Reichle, A., Andreesen, R., Rockelein, G., Dietmaier, W., Ruschoff, J., Blaszyk, H., Hofstadter, F., Hartmann, A.
(2004). Microsatellite Instability Predicts Poor Short-Term Survival in Patients with Advanced Breast Cancer after High-Dose Chemotherapy and Autologous Stem-Cell Transplantation. Clin. Cancer Res.
10: 556-564
[Abstract][Full Text]
Mariadason, J. M., Arango, D., Shi, Q., Wilson, A. J., Corner, G. A., Nicholas, C., Aranes, M. J., Lesser, M., Schwartz, E. L., Augenlicht, L. H.
(2003). Gene Expression Profiling-Based Prediction of Response of Colon Carcinoma Cells to 5-Fluorouracil and Camptothecin. Cancer Res.
63: 8791-8812
[Abstract][Full Text]
Cortellino, S., Turner, D., Masciullo, V., Schepis, F., Albino, D., Daniel, R., Skalka, A. M., Meropol, N. J., Alberti, C., Larue, L., Bellacosa, A.
(2003). From The Cover: The base excision repair enzyme MED1 mediates DNA damage response to antitumor drugs and is associated with mismatch repair system integrity. Proc. Natl. Acad. Sci. USA
100: 15071-15076
[Abstract][Full Text]
Allegra, C. J., Kim, G., Kirsch, I. R., Iacopetta, B., Elsaleh, H., Zeps, N., Jimenez, J. J., Blanes, A., Diaz-Cano, S. J., Gryfe, R., Ribic, C. M., Sargent, D. J.
(2003). Microsatellite Instability in Colon Cancer. NEJM
349: 1774-1776
[Full Text]
(2003). Colon Tumors with Microsatellite Instability: No Response to Fluorouracil-Based Adjuvant Chemotherapy. JWatch Gastroenterology
2003: 2-2
[Full Text]
Previous
